Evaluating the Rationality of the International Guideline's Recommendations Regarding Selective Coverage of Level Ib in Node Clinical Target Volume with Nasopharyngeal Carcinoma: Results from a Real-World Series.

Q. Guo,N. Xiao, H. Xu,J. Zong, Y. Xiao,T. Lu, Y. Xu, B. Chen, C. Hu,X. Zhang, J. Pan, S. Lin

International journal of radiation oncology, biology, physics（2021）

引用 0|浏览24

暂无评分

摘要

Level Ib-sparing IMRT should be safe and feasible for patients who only had involvement of level II LNs with ECE, and/or had a MAD of greater than 2 cm in level II LNs, and/or Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted to confirm our results.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要